Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension is a research paper published in JACC Basic to Translational Science (2021). On theSindex it has a DataRank of 0.606. It has been cited 56 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.606
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NHLBI NIH HHS
Grant: R01 HL134893
NHLBI NIH HHS
Grant: R01 HL140224
NHLBI NIH HHS
Grant: K24 HL153669
NHLBI NIH HHS
Grant: T32 HL094301
National Institutes of Health
Grant: 1K24HL153669-01
Mentoring in Patient-Oriented and Translational HFpEF Research
National Institutes of Health
Grant: 1R01HL140224-01
Eicosanoid Profiles as Determinants of HFpEF
National Institutes of Health
Grant: 5T32HL094301-07
Noninvasive Cardiovascular Imaging Research Training Program
National Institutes of Health
Grant: 1R01HL134893-01A1
The Association of Metabolic Disease and Pulmonary Hypertension
Gilead Sciences
National Institutes of Health
FWCI
3.23
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission
Additional file 1 of Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission